Aztherapies Inc., of Boston, said it closed a $26.3 million series C preferred equity financing co-led by Spinnaker Capital and Cosine, with participation from new and existing investors, including Drads Capital, IBS Capital and Wexford Capital.
It was at the constantly changing intersection of data science that Arsenal Biosciences Inc.'s CEO, Ken Drazan, found himself as he helped bring the company to life and to its $85 million series A fundraising.
PARIS – Incepto Medical SAS, of Paris, raised $6.2 million from three French venture capital funds – Axa Venture Partners, Bpifrance through its Patient Autonome Fund, and Cap Decisif – to develop its artificial intelligence (AI) medical imaging platform. "This funding round is a first step toward accelerating [the] rollout of our [AI] medical imaging solutions on a grand scale throughout France," Incepto CEO Antoine Jomier told BioWorld MedTech.
TORONTO – A total of $1.4 million in capital funding from 12 U.S., Canadian and European angel investors will help Toronto-based Cohesys Inc. complete preclinical animal studies, with an eye toward gaining approval for its nontoxic, adhesive tape for rebuilding facial bones.
HONG KONG – Upin & Co. Ltd., a fund and asset management company headquartered in London, plans to invest a total of KRW2 trillion (US$1.7 billion) over three years in the South Korean biopharma industry.
HONG KONG – Kobiolabs Inc., a microbiome-based venture from Seoul, South Korea, has secured a KRW26.6 billion (US$22.2 million) investment. Founded in 2014, the venture has achieved KRW193 billion of enterprise value.
HONG KONG – South Korean pharmaceutical company Chong Kun Dang Holdings recently invested KRW5 billion (US$4.1 million) in Biorchestra Co. Ltd., a Korean startup based in Daejeon that aims to develop Alzheimer’s dementia treatment based on microRNA.
Cyteir Therapeutics Inc., a Lexington, Mass.-based company exploiting synthetic lethality to fight cancer, is extending its series B financing with $40.2 million to support a recently launched phase I/II study of its lead candidate, CYT-0851, an oral small-molecule inhibitor of the protein RAD51.